Agenus (NASDAQ:AGEN) Earns “Neutral” Rating from HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports.

Agenus Stock Performance

Shares of AGEN stock opened at $3.83 on Wednesday. Agenus has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The firm has a market cap of $89.85 million, a P/E ratio of -0.34 and a beta of 1.27. The business’s 50 day moving average price is $3.12 and its 200-day moving average price is $5.04.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Blair William & Co. IL purchased a new position in shares of Agenus during the second quarter valued at about $441,000. Point72 DIFC Ltd purchased a new position in shares of Agenus during the 2nd quarter worth approximately $51,000. Squarepoint Ops LLC purchased a new position in shares of Agenus during the 2nd quarter worth approximately $614,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Agenus in the 2nd quarter worth approximately $106,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Agenus in the 2nd quarter valued at approximately $1,050,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.